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SUMMARY
Impact of Hormone Treatment and Photodynamic Therapy (PDT)
on Human Keratoconus Keratocytes in Vitro
Background and purposes: Keratoconus is a multi-factorial disease causing corneal
degeneration, thinning and secondary ectasia, which can severely degrade visual
performance. Its pathophysiology is unknown but suggested aetiological factors
include oxidative damage, repetitive mechanical injury, immunological factors and
genetic factors. In addition, hormonal factors have been shown to play a potential role.
PDT is based on a photosensitizer activated by light of appropriate wavelength, which
leads to generation of singlet oxygen and free radicals, responsible for the cytotoxic
effect on microorganisms. Thus, it is important to determine the influence of PDT on
human keratoconus keratocytes.
The purpose of this study was:
 To investigate the impact of thyroxine and hydrocortisone on the viability,
proliferation and apoptosis of human keratocytes in vitro in normal and
keratoconus corneas.
 To investigate the impact of thyroxine and hydrocortisone on the secretion of
growth factors and interleukins by normal human keratocytes and keratoconus
keratocytes in vitro.
 To determine the impact of riboflavin-UVA-PDT on viability, apoptosis,
proliferation and activation of human keratoconus keratocytes, in vitro.
 To determine the impact of crosslinking on growth factor and interleukin
secretion of human keratoconus keratocytes, in vitro
Methods: Primary human keratocytes were isolated by digestion in collagenase (1.0
mg/ml) from human corneal buttons and cultured in DMEM/Ham's F12 medium
supplemented with 10% fetal calf serum. Keratocytes either were seeded and treated
with thyroxine and hydrocortisone in concentrations of 0, 1, 10 and 20 µg/ml for 24
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hours, or underwent UVA illumination (370 nm) for 4 minutes and 10 seconds with an
irradiation dose of 8 mW/cm2 (2 J/cm2) during exposure to 0.05% or 0.1% riboflavin
and 20% dextran in PBS. In supplementary experiment of cell proliferation test, cells
were also treated with Fibroblast Growth Factor basic (FGFb) in 1ng/ml, and
Transforming Growth Factor beta 1 (TGFβ1) in 2ng/ml for 24h.
Twenty-four hours after hormone treatment or PDT, human keratocyte viability was
evaluated by the Alamar blue assay, apoptosis and total DNA content of the cells
using the APO-DIRECT TM Kit and cell proliferation by the BrdU Cell Proliferation
Assay Kit.
CD34 and alpha smooth muscle actin (α-SMA) expression of human keratocytes was
analyzed using flow cytometry (FACS) after illumination following exposure to 0.1%
riboflavin in the culture medium. In addition, five and twenty-four hours after
hormone treatment or illumination, the secretion of IL-1β, IL-6, IL-8, FGFb, HGF,
KGF, TGFβ1, EGF, MIP1α, MMP-9 and TNFα of human keratocytes was measured
by enzyme-linked immunoabsorbent assay (ELISA).
Results: Twenty-four hours after hormone treatment, we did not observe any changes
in cell viability or apoptosis of normal keratocytes and keratoconus keratocytes. Cell
proliferation of normal keratocytes increased significantly 24h after treatment with
thyroxine from concentration of 1 µg/ml and higher (p<0.01), but there were no
changes with hydrocortisone. Significant increase of proliferation in keratoconus
keratocytes was only detected in the 20 µg/ml thyroxine group (p<0.05), and there
were also no changes with hydrocortisone. Proliferation increased on normal
keratocytes (p<0.01, p<0.01) and decreased on keratoconus keratocytes (p<0.01,
p<0.01) significantly after FGFb and TGFβ1 treatment for 24h.
In normal keratocytes, treatment with thyroxine significantly down-regulated the
secretion of IL-6 at 5h and up-regulated the secretion of HGF at 24h, while treatment
with hydrocortisone significantly down-regulated the secretion of IL-6, IL-8 and
FGFb at 5h, as well as the secretion of IL-6, IL-8, EGF and TGFβ1 at 24h. In
keratoconus keratocytes, treatment with thyroxine significantly up-regulated the
secretion of IL-8 and TNFa at 5h, as well as the secretion of HGF at 24h, whereas
treatment with hydrocortisone significantly down-regulated the secretion of IL-6, IL-8
and TNFa at 5h, significantly down-regulated the secretion of IL-6 and TGFβ1 at 24h
and significantly up-regulated the secretion of HGF at 24h.
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Using riboflavin or UVA light only, we did not detect significant changes of cell
viability, apoptosis, proliferation, CD34 or α-SMA expression. Using
riboflavin-UVA-PDT, cell viability decreased significantly at 0.1% (p<0.05), the
percentage of apoptotic KC keratocytes increased significantly at 0.05% and 0.1%
(p<0.05 for both) and proliferation was inhibited at 0.05 and 0.1% (p=0.009 for both)
riboflavin concentrations, compared to untreated controls. Following
riboflavin-UVA-PDT, CD34 and alpha-smooth muscle actin expression of KC
keratocytes remained unchanged compared to controls (p>0.06).
KGF and IL-1β secretion of keratocytes were below the measurement limit for all
timepoints. Using riboflavin or UVA light illumination separately, growth factor and
interleukin secretion of keratocytes remained unchanged for both time points (p>0.35).
Five hours after crosslinking, FGFb secretion of keratoconus keratocytes increased (p
= 0.037) significantly compared to untreated controls, whereas HGF, TGFβ1, VEGF,
IL-6, and IL-8 secretion remained unchanged. 24 hours following CXL, none of the
growth factor and interleukin concentrations differed significantly from untreated
controls (p>0.12).
Conclusions:
 Thyroxine and hydrocortisone appear to have no significant impact on cell
viability and apoptosis of human keratocytes in vitro. Treatment with thyroxine
triggers the proliferation of normal keratocytes much more effectively than that of
keratoconus keratocytes. FGFb and TGFβ1 increased proliferation of normal
keratocytes and decreased that of keratoconus keratocytes. Hydrocortisone does
not affect significantly cell proliferation of normal keratocytes and keratoconus
keratocytes.
 Thyroxine significantly up-regulates the secretion of certain growth factors and
interleukins by keratoconus keratocytes in vitro, although it does not affect their
secretion by normal keratocytes. Hydrocortisone predominatly down-regulates
the secretion of certain growth factors and interleukins by normal and
keratoconus keratocytes. It appears that hormonal influences have differential
effects on the secretion of these factors by human keratocytes, thereby
modulating to some extent the corneal homeostasis.
 Crosslinking/riboflavin-UVA-PDT decreases viability, triggers apoptosis and
inhibits proliferation, however this does not have an impact on multipotent
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haematopoietic stem cell transformation and myofibroblastic transformation of
human KC keratocytes in vitro.
 Crosslinking triggers FGFb secretion of keratoconus keratocytes transiently (5
hours), which normalizes after 24 hours. Crosslinking does not seem to have an
impact on HGF, TGFβ1, VEGF, KGF, IL-1β, IL-6, and IL-8 secretion of
keratoconus keratocytes in the short term.
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ZUSAMMENFASSUNG
Auswirkung der Hormonbehandlung und der Photodynamischen Therapie (PDT)
auf Humane Keratokonus Keratozyten in Vitro
Hintergrund/Ziele: Keratokonus stellt eine multifaktorielle Hornhautdegeneration
dar, welche eine ausgeprägte Hornhautverdünnung und Hornhautektasie induziert,
und dadurch die Sehschärfe erheblich beeinträchtigen kann. Die Pathophysiologie des
Keratokonus ist nicht vollständig bekannt. Es wird allerdings vermutet, dass
oxidativer Stress, mechanische Hornhautverletzung aufgrund regelmäßigen
Augenreibens, immunologische Faktoren sowie genetische Faktoren eine wichtige
Rolle spielen. Außerdem sind hormonelle Einflüsse von besonderer Bedeutung in der
Pathogenese des Keratokonus. Die photodynamische Therapie (PDT) basiert auf der
Photoaktivierung eines Photosensibilisators unter dem Einfluss von Licht einer
bestimmten Wellenlänge, welches die Bildung von aggressiven freien Radikalen
verursacht und dadurch zum Zelltod (zytotoxischer Effekt) führen kann. Aus diesen
Gründen ist es sehr bedeutsam, die Auswirkung der PDT auf die humanen
keratokonischen Keratozyten zu untersuchen.
Die Ziele dieser Studie sind:
 Die Untersuchung des Effekts von Thyroxin und Hydrokortison auf die Viabilität,
Proliferation und Apoptose humaner Keratozyten aus normalen und
keratokonischen Hornhäuten in vitro.
 Die Untersuchung des Effekts von Thyroxin und Hydrokortison auf die Sekretion
verschiedener Wachstumsfaktoren und Interleukinen von normalen humanen
Keratozyten und keratokonischen Keratozyten in vitro.
 Die Untersuchung des Effekts von Thyroxin und Hydrokortison auf die
Expression von CD34 und alpha smooth muscle actin (α-SMA) von normalen
humanen Keratozyten und keratokonischen Keratozyten in vitro.
 Die Untersuchung des Effekts von Riboflavin-UVA-PDT auf die Viabilität,
SUMMARY xi
Proliferation und Apoptose humaner keratokonischer Keratozyten in vitro.
 Die Untersuchung des Effekts von Riboflavin-UVA-PDT auf die Sekretion
verschiedener Wachstumsfaktoren und Interleukinen von humanen
keratokonischen Keratozyten in vitro.
 Die Untersuchung des Effekts von Riboflavin-UVA-PDT auf die Expression von
CD34 und alpha smooth muscle actin (α-SMA) von normalen humanen
Keratozyten und keratokonischen Keratozyten in vitro.
Methode: Primäre humane Keratozyten wurden durch Kollagenasen-Verdau (1.0
mg/ml) aus humanen Hornhauttransplantaten isoliert und in DMEM/Ham's F12
Medium mit 10% fetalem Kälberserum kultiviert. Die Keratozyten wurden entweder
mit Thyroxin und Hydrokortison in verschiedenen Konzentrationen (0, 1, 10 und 20
µg/ml) über 24 Stunden kultiviert, oder mit Riboflavin-UVA über einem Zeitraum von
4 Minuten und 10 Sekunden behandelt. Die Lichtquelle hat eine Wellenlänge von 375
nm und eine Bestrahlungsstärke von 8 mW/cm2 bei einer Energiedosis von 2 J/cm2.
Riboflavin-5-phosphat wurde in Konzentrationen von 0%, 0.05% und 0.1% mit 20%
Dextran in PBS eingesetzt. In weiteren Experimenten wurden die Keratozyten mit
Fibroblast Growth Factor basic (FGFb) mit der Konzentration von 1 ng/ml, und
Transforming Growth Factor beta 1 (TGFβ1) mit der Konzentration von 2 ng/ml
über 24 Stunden kultiviert.
Vierundzwanzig Stunden nach Hormonbehandlung oder PDT wurde die Viabilität
photometrisch mit dem alamarBlue® Assay, die Apoptose durchflusszytometrisch mit
dem APO- DIRECTTM Kit und die Zellproliferation photometrisch mit dem BrdU Cell
Proliferation ELISAKit evaluiert.
Die Sekretion von IL-1β, IL-6, IL-8, FGFb, HGF, KGF, TGFβ1, EGF, MIP1α,
MMP-9 und TNFα von humanen Keratozyten (5 Stunden und 24 Stunden) nach
Hormonbehandlung oder Riboflavin-UVA-Bestrahlung wurde photometrisch mit
einem Enzyme-linked immunosorbent assay (ELISA) bestimmt.
Die Bestimmung der Expression von CD34 und Alpha Smooth Muscle actin(α-SMA)
erfolgte durchflusszytometrisch unter Verwendung spezifischer fluoreszenzmarkierter
Antikörper.
Ergebnisse: Vierundzwanzig Stunden nach Hormonbehandlung konnten keine
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Unterschiede der Viabilität und Apoptose zwischen normalen Keratozyten und
keratokonischen Keratozyten nachgewiesen werden. Die Proliferation der normalen
Keratozyten war signifikant erhöht nach der Applikation von Thyroxin ab der
Konzentration von 1 µg/ml (p<0.01), aber es zeigten sich keine Unterschiede nach
Hydrokortisongabe.
Die Proliferation der keratokonischen Keratozyten war nur signifikant erhöht mit
einer Thyroxinkonzentration von 20 µg/ml (p<0.05) und es zeigten sich ebenfalls
keine Unterschiede nach Hydrokortisongabe.
Nach Zugabe von FGFb und TGFβ1 über 24 Stunden stieg die Proliferation der
normalen Keratozyten signifikant an (p<0.01, p<0.01) und die Proliferation der
keratokonischen Keratozyten sank signifikant ab (p<0.01, p<0.01).
Die Applikation von Thyroxin zu normalen Keratozyten führte zur signifikanten
Reduzierung der IL-6-Sekretion nach 5 Stunden und zu einem Anstieg der
HGF-Sekretion nach 24 Stunden. Der Zusatz von Hydrokortison induzierte eine
signifikante Abnahme der IL-6-, IL-8- und FGFb-Sekretion nach 5 Stunden, sowie der
IL-6-, IL-8-, EGF- und TGFβ-Sekretion nach 24 Stunden. Die Zugabe von Thyroxin
zu keratokonischen Keratozyten führte zu einem signifikanten Anstieg der IL-8- und
TNFa-Expression nach 5 Stunden, sowie des Anstiegs der HGF-Sekretion nach 24
Stunden. Der Zusatz von Hydrokortison induzierte eine signifikante Abnahme der
IL-6-, IL-8- und TNFa-Sekretion nach 5 Stunden, und der IL-6- und TGFβ-Sekretion
nach 24 Stunden, sowie einen signifikanten Anstieg der HGF-Konzentration nach
24 Stunden.
Nach Riboflavin-Behandlung oder UVA-Bestrahlung konnten keine Unterschiede der
Viabilität, Apoptose, Proliferation, CD34- oder α-SMA-Expression nachgewiesen
werden. Nach Riboflavin-UVA-PDT sank die Viabilität signifikant bei der
Konzentration von 0.1 % (p<0.05). Die Apoptose der keratokonischen Keratozyten
stieg signifikant bei Konzentrationen von 0.05% und 0.1% (p<0.05). Die
Proliferationsrate nahm bei Konzentrationen von 0.05 und 0.1% (p=0.009 für beide)
im Vergleich zur Kontrolle ab. Nach Riboflavin-UVA-PDT blieb die Expression von
CD34 und α-SMA der keratokonischen Keratozyten unverändert (p>0.06).
Nach Riboflavin-Behandlung oder UVA-Bestrahlung blieb die Sekretion von
Wachstumsfaktoren und Interleukinen der Keratozyten unverändert (p>0.35). Fünf
Stunden nach Crosslinking stieg die Sekretion von FGFb signifikant an (p = 0.037),
wobei die Sekretion von HGF, TGFβ1, VEGF, IL-6, und IL-8 unverändert blieb.
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Vierundzwanzig Stunden nach Crosslinking blieb die Expression von
Wachstumsfaktoren und Interleukinen der Keratozyten unverändert (p>0.12).
Schlußvolgerungen:
 Thyroxin und Hydrokortison haben keinen Einfluss auf die Viabilität und
Apoptose humaner Keratozyten in vitro. Die Zugabe von Thyroxin stimuliert die
Proliferation normaler Keratozyten stärker als die Proliferation keratokonischer
Keratozyten. FGFb und TGFβ1 induzieren einen Anstieg der Proliferation
normaler Keratozyten und eine Abnahme der Proliferation keratokonischer
Keratozyten. Hydrokortison hat keinen signifikanten Einfluss auf die
Proliferation normaler und keratokonischer Keratozyten.
 Thyroxin stimuliert die Sekretion Wachstumsfaktoren und Interleukinen von
keratokonischen Keratozyten in vitro, aber nicht die Sekretion von
Wachstumsfaktoren und Interleukinen von normalen Keratozyten. Hydrokortison
vermindert die Sekretion Wachstumsfaktoren und Interleukinen sowohl von
normalen als auch von keratokonischen Keratozyten in vitro. Diese Ergebnisse
weisen darauf hin, dass die hormonellen Einflüsse differenzierte Effekte auf die
Sekretion von Wachstumsfaktoren und Interleukinen von normalen und
keratotokonischen Keratozyten haben.
 Riboflavin-UVA-PDT reduziert die Viabilität und Proliferation und erhöht die
Apoptose der Keratozyten. Allerdings zeigt sich keine Auswirkung auf die
Stammzelltransformation und myofibroblastische Transformation humaner
keratokonischer Keratozyten in vitro.
 Riboflavin-UVA-PDT induziert die Sekretion des FGFb von keratokonischen
Keratozyten nach 5 Stunden, welche sich nach 24 Stunden normalisiert.
Riboflavin-UVA-PDT hat keinen signifikanten Einfluss auf die Sekretion der
HGF-, TGFβ1-, VEGF-, KGF-, IL-1β-, IL-6-, und IL-8-Expression von
keratokonischen Keratozyten.
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1 INTRODUCTION
Eye is the most sophisticated optical instrument in human body. A healthy, clear
cornea is essential for good vision. Cornea is the anterior front part of the eye in front
of lens, vitreous body and retina. The cornea contributes to approximately
three-quarters of the total optical power of the eye. 1 Corneal opacities due to infection,
injury or any other ocular surface diseases interfere with vision.
Keratoconus is a bilateral corneal degeneration, which is characterized by marked
corneal thinning and conical protrusion of the cornea, which can severely degrade
visual performance.2 The etiology and pathophysiology of keratoconus is
multifactorial and has not been elucidated yet. A number of investigators, including
our group, have reported that fluctuation of hormones and cytokines may play a
function in the exacerbation or even initiation of keratoconus. 3-8
In recent years, the technique of corneal collagen crosslinking (CXL) has been
developed with its several advantages to stop the progression of keratoconus. 9,10 CXL
is also being applied as an alternative treatment for persistent infectious keratitis and it
offers a potential treatment alternative. 11,12
In this work, we describe the challenges in diagnosis and management of keratoconus.
We also investigate the impact of hormone treatment and PDT on human keratoconus
keratocytes in vitro, which may play important roles in initiation, exacerbation or
inhibition of progressive keratoconus.
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1.1 Corneal anatomy
1.1.1 General aspects
The normal cornea is mostly horizontally elliptical with an average diameter of 11.5
mm vertically and 12.0 mm horizontally. The average thickness of the central cornea
is 0.54 mm, and it becomes thicker towards the periphery. 1
The cornea is free of blood vessels and is nourished from the aqueous humor of the
anterior chamber and through the tear fluid. The cornea is innervated through a
subepithelial and a deeper stromal plexus, which are richly supplied by numerous
sensory nerve endings of the first division of the trigeminal nerve.
1.1.2 Corneal layers
The human cornea consists of five layers, from anterior to posterior the epithelium,
Bowman's layer, the stroma, Descemet's membrane and the endothelium. Each layer
plays an important and distinct role in corneal physiology and pathophysiology.
1) Epithelium
The corneal epithelium is the outermost layer of the cornea. It is on average
0.04-0.06 mm thick and is composed of multiple epithelial cell layers. There are
three different types of cells: the basal, wing and squamous cells. The basal cells
are adhered to the underlying basement membrane. Above them, there are two or
three layers of wing cells and two layers of superficial squamous cells, adjacent
to the tear film. The superficial cells with many microplicae and microvilli are
involved in the stabilization of the tear film and the absorption of nutrients. In
addition, highly resistant tight junctions formed between adjacent epithelial cells
provide a protective barrier, which is essential for good corneal optical properties
during continuous renewal of the corneal epithelium. 13,14
Limbal stem cells are indispensable for the maintenance of a healthy corneal
surface. These are principally located at the basal layer of the palisades of Vogt at
the cornea conjunctival junction. 15-17 The deficiency of limbal stem cells may
result in conjunctival epithelial ingrowth, neovascularization, chronic
inflammation or recurrent epithelial erosions and defects. 18,19
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2) Bowman's layer
The corneal Bowman’s layer is an acellular superficial layer of the stroma
consisting of collagen fibers. The Bowman's layer is a visible indicator of
ongoing stromal-epithelial interactions in the cornea. However, its critical
function in corneal physiology is still unclear. 20
3) Stroma
The stroma is the transparent middle layer of the cornea, which is about
0.40-0.50 mm thick. It accounts for about 90% of the total corneal thickness. The
corneal stroma is also called substantia propria. It comprises arranged collagen
fibers with sparsely distributed interconnecting keratocytes. The maintenance of
lattice arrangement and spacing of collagen fibrils is critical for the transparency
of the cornea. 21,22
Under normal circumstances, stromal keratocytes are rarely dividing cells.
However, keratocytes can proliferate and migrate in case of tissue damage and
transform into activated fibroblasts or/and myofibroblasts. They also produce
collagen and proteoglycans for repair when an injury occurs in the stroma. 23
4) Descemet's membrane
The Descemet's membrane consists of a fine latticework of collagen fibrils,
which are distinct from the collagen lamellae of corneal stroma. It serves as a
protective barrier against infection and injuries. Descemet's membrane contains 3
zones: an anterior perinatal zone which is deposited in utero; a middle adult zone;
a posterior zone, which serves as a modified basement membrane for the
endothelium. 24
5) Endothelium
The corneal endothelium is approximately 0.005 mm thick. It is a monolayer of
cells at the posterior surface of the cornea. Endothelium is essential in keeping
the cornea transparent, as it is responsible for a dynamic balance between a
“leaky” barrier for fluid moving into the stroma and a fluid pump to actively
move fluid from the stroma back into the anterior chamber of the eye. 25-27
Corneal endothelial cells have a limited regenerative potential in vivo. The cell
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density in human adult is approximately 2500 cells/mm². This number steadily
decreases with advancing age, 28 diseases 29 and intraocular surgery. 30
Maintenance of corneal transparency can be lost when endothelial cell density is
below a critical level.
Figure 1. The human cornea in cross-section. 14
At the outer surface of the cornea, there is an epithelial layer adhered to a basement
membrane above Bowman's layer. The stromal layer is sparsely populated with
keratocytes. The single sheet of endothelial cells sits on Descemet's membrane.
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1.2 Keratoconus
1.2.1 Definition and Epidemiology
Keratoconus (KC) is the most common primary ectasia, characterized by localized
corneal thinning leading to protrusion of the thinned cornea. It usually occurs in the
second decade of life and affects both genders and all ethnicities. 2,31 The estimated
prevalence in the general population is 54 per 100,000. 32
1.2.2 Etiology
Pathophysiology is unknown but suggested aetiological factors include repetitive
mechanical injury (including eye rubbing), oxidative damage, genetic and
immunological factors. 2 In addition, hormonal factors have been shown to play a
potential role. 3-5A number of investigators have reported that hypothyroidism may
play a function in the exacerbation or even initiation of keratoconus. 3,4Others have
demonstrated a possible role of tear fluid thyroxine in keratoconus development. 5
Certainly, thyroid hormones are known to be important in corneal dehydration and
transparency during embryonic development. 33 Conrad et al. have reported
expression of thyroxine receptor A (THRA) mRNA in all layers of embryonic chicken
corneas, with keratocytes and endothelial cells expressing thyroxine receptor B
(THRB) mRNA. 34
Corneal tissue degradation in keratoconus involves the expression of inflammatory
mediators, such as pro-inflammatory cytokines, cell adhesion molecules, and matrix
metalloproteinases.
Although keratoconus has been primarily defined as a non-inflammatory corneal
disease, it has been reported that inflammatory molecules such as interleukin 1α and
tumor necrosis factor α are over-expressed in keratoconus corneas as well as in the
tear film of patients with keratoconus. 6-8
1.2.3 Clinical features and diagnosis
Clinical features of keratoconus includes progressive corneal thinning and corneal
protrusion, thereby inducing high myopia and irregular astigmatism, which severely
affect visual acuity. In order to achieve sufficient visual restoration, approximately
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20% of the keratoconus patients require penetrating keratoplasty after two decades. 35
Computer-assisted corneal topography is recognized as the “gold standard” for the
diagnosis of keratoconus. 36 Placido-based modalities or Scheimpflug camera-based
systems are important for the diagnosis of keratoconus, which facilitate an accurate
analysis of both anterior and posterior corneal surface, thereby providing valuable
topographic and pachymetric data. 37,38
1.2.4 Treatment
In early stages of keratoconus, soft contact lenses are employed. As the condition
progresses, rigid, gas-permeable (RGP) lenses are commonly accepted. But none of
the contact lenses arrest progression of the condition. 39
Corneal collagen crosslinking with riboflavin, also known as CXL and CCL, involves
a one-time application of riboflavin solution to the eye that is activated by
illumination with UVA light for approximately 30 minutes. 40,41 The riboflavin causes
new bonds to form across adjacent collagen strands in the stromal layer of the cornea,
which recovers and preserves some of the cornea's mechanical strength.
Keratoconus is the most common disease for conducting a penetrating keratoplasty,
generally accounting for about a quarter of such procedures. 42 A recent surgical
alternative to corneal transplant is the insertion of intrastromal corneal ring segments.
The segments push out against the curvature of the cornea, flattening the peak of the
cone and returning it to a more natural shape. The procedure involves no removal of
eye tissue. 43
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1.3 Hormones
1.3.1 Thyroxine
Triiodothyronine (T3) and thyroxine (T4), are tyrosine-based hormones produced by
the thyroid gland that are primarily responsible for regulation of metabolism. The
major form of thyroid hormone in the blood is thyroxine. Thyroxine is essential to
proper development and differentiation of all cells of the human body, which regulates
protein, fat, and carbohydrate metabolism, affecting how human cells use energetic
compounds. A number of physiological and pathological stimuli influence thyroid
hormone synthesis.
Figure 2. Thyroxine (3,5,3',5'-tetraiodothyronine)
1.3.2 Effect of thyroxine on the cornea
Although the etiology of keratoconus has not been clearly clarified, a number of
investigators have reported that hypothyroidism may play a function in the
exacerbation or even initiation of keratoconus. 3,4Others have demonstrated a possible
role of tear fluid thyroxine in keratoconus development. 5 Certainly, thyroid hormones
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are known to be important in corneal dehydration and transparency during embryonic
development. 33 Thyroxine receptor A (THRA) mRNA was found in all layers of
embryonic chicken corneas, with keratocytes and endothelial cells expressing
thyroxine receptor B (THRB) mRNA.34
1.3.3 Hydrocortisone
Cortisol is a steroid hormone, more specifically a glucocorticoid, produced by the
zona fasciculata of the adrenal cortex. 44 Hydrocortisone is an identical molecule to
cortisol, which can be used to treat people who lack adequate stores of endogenous
cortisol. It is released in response to stress and a low level of blood glucocorticoid. Its
primary functions are to increase blood sugar through gluconeogenesis, suppress the
immune system, and aid with fat, protein, and carbohydrate metabolisms. 44 It also
decreases bone formation. 45
FIgure 3. Hydrocortisone ((11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione)
1.3.4 Effect of hydrocortisone on the cornea
Hydrocortisone down-regulates the expression of Toll-like receptor-2 and -4 by
corneal keratocytes in vitro, 46 thereby modulating the innate corneal immune system,
since Toll-like receptors stimulate the pro-inflammatory cytokines and chemokines,
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such as TNF-α, IL-6, IL-8, IL-18, and monocyte chemotactic protein-1. 47,48 The
release of IL-6 and IL-8 is inhibited by hydrocortisone in vitro. 49
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1.4 Photodynamic Therapy
1.4.1 Definition of PDT
Photodynamic therapy (PDT) is a promising treatment for cancer and other diseases.
PDT involves the application of a photosensitizer (PS) compound followed by
exposure to light of appropriate wavelength. It results in production of reactive
oxygen species (ROS) leading to cell death and/or tissue damage.
The first observation of tissue photochemical sensitization by the interaction between
light and a chemical drug was reported by Raab 50 in 1900. He discovered a lethal
effect on Infusoria, a species of paramecium, dependent on a combination of acridine
red and light. Furthermore, Tapperner and Jesionek 51 used a combination of topically
applied fluorescent substance of eosin and white light to treat skin tumors, which was
considered as the first medical application of PDT. Over the past century, PDT was
widely used in clinical treatment. The combination of cell or tissue selective PS
uptake and local light exposure provided a potential effective approach to cancer 52
and infectious disease 53 treatment. It has efficient cytotoxicity, but limited damage to
the surrounding normal cells or tissues.
1.4.2 Photochemistry of PDT
The photochemical reaction is represented at the Jablonski diagram. 54 Through
illumination with light of appropriate wavelength, the PS in a singlet state (S0) is
excited from ground state to the first excited singlet state (S1) and the second excited
singlet state (S2).
Following excitation, the molecule can relax back to the ground state by emitting
fluorescence or through nonradioactive relaxation quenching processes, but can also
be converted to the excited triplet state (T1) with a longer life-time. The T1 can return
to the ground state by emitting phosphorescence and can also undergo type I (electron
transfer) and/or type II (energy transfer) reactions to produce highly reactive oxygen
species (ROS). 52, 55
INTRODUCTION 11
Figure 4. Jablonski diagram representing the excitation and relaxation of a
photosensitizer (PS), with type I and type II photoreactions.
S0 = ground singlet state; S1 = first excited singlet state; S2 = second excited singlet
state. 54
Generally, in the type I reaction free oxygen radicals formed by the electron-transfer
reaction between the excited triplet state and a substrate molecule produce ROS
including hydrogen peroxide (H2O2) and superoxide anion (O2-). In the type II
reaction, the direct energy-transfer of T1 leads to the formation of highly reactive
singlet oxygen (1O2). Singlet oxygen is an electronically excited state of molecular
oxygen and has a short life-time in biologic systems and a short radius of action 56.
Thus, the reaction of reactive singlet oxygen can lead to a localized response without
damaging distant cells or tissues. It is not only generally accepted that Type II
reactions play a dominant effect in application of PDT in cancer treatments, 57-59 but
also seems to be the major pathway in reduction of organism damage in antimicrobial
PDT. 61-63
1.4.3 Light sources
Visible light has a wavelength spectrum within the range of approximately 400-700
nm between the invisible ultraviolet (UV) and the invisible infrared rays (IR). 64
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Figure 3. http://en.wikipedia.org/wiki/File:EM_spectrum.svg
The use of light as a therapeutic agent originates from the ancient Egypt, India and
China. It was used to treat skin diseases such as psoriasis, vitiligo and also in cancer
and psychosis. 65
PDT requires a source of light to activate the PS. The activating light is most often
generated by lasers as they possess a high power density, a monochromatic character
(light of one wavelength) and high local and temporal coherence. 66,67 The energy
absorbed by the PS in a volume of tissue, can be calculated exactly if the fluence rate
of light, drug concentration and the absorption coefficient are defined at all times in
the concrete tissue volume. 68 During PDT, the depth of light penetration into the
tissue varies with the optical properties of the tissue and the wavelength of light,
which may be a critical factors contributing to efficacy of PDT. 69,70
1.4.4 Photosensitizers
The majority of Photosensitizers(PSs) possess a porphyrin ring structure which is
similar to that of chlorophyll or heme in hemoglobin. The structure of PSs plays a key
role in their success as a PDT agent. The PSs absorb light of a specific wavelength,
which results in the transfer and translation of light energy into chemical reaction in
the presence of molecular oxygen and then in production of singlet oxygen or
superoxide. These molecules induce cell damage through direct or indirect
cytotoxicity. 71 Therefore, the PS is considered to be a critical component in PDT
procedures.
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Since the first observation of tissue photochemical sensitization reported by Raab 50 in
1900, many new PSs were synthesized and analysed over the past century.
In clinical application, PSs are divided into three families such as porphyrin,
chlorophyll and dye. Generally, the porphyrins, developed in the 1970s and early
1980s, are called first generation PSs. Porphyrin derivatives were developed since the
late 1980s and are called second generation PSs. Third generation PSs are available
drugs modificed with biologic conjugates to increase the affinity of the PS for the
tissue. 72,73 The fact that different generations of PSs exist does not mean that newer
generation drugs in clinical application are better than older drugs. 71
Riboflavin, also known as vitamin B2 and is the vitamin formerly known as G, 74 is an
easily absorbed colored micronutrient with a key role in maintaining health in humans
and other animals. Riboflavin in combination with UV light has been shown to be
effective in reducing the ability of harmful pathogens found in blood products to
cause disease. 75-78 Recently, riboflavin has been used in a new treatment to slow or
stop the progression of the corneal disorder keratoconus, which is called corneal
collagen crosslinking (CXL). In corneal crosslinking, riboflavin drops are applied to
the patient’s corneal surface. Once the riboflavin has penetrated through the cornea,
ultraviolet A light therapy is applied. This induces collagen crosslinking, which
increases the tensile strength of the cornea. 40,41
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1.5 Thesis aims
Keratoconus is a multi-factorial disease causing corneal degeneration, thinning and
secondary ectasia, which can severely degrade visual performance. Its
pathophysiology is unknown, but suggested aetiological factors include oxidative
damage, repetitive mechanical injury, immunological factors and genetic factors. In
addition, hormonal factors have been shown to play a potential role. PDT is based on
a photosensitizer activated by light of appropriate wavelength, which leads to
generation of singlet oxygen and free radicals, responsible for the cytotoxic effect on
microorganisms. Thus, it is important to determine the influence of PDT on human
keratoconus keratocytes.
The purpose of this study was:
 To investigate the impact of thyroxine and hydrocortisone on the viability,
proliferation and apoptosis of human keratocytes in vitro in normal and
keratoconus corneas.
 To investigate the impact of thyroxine and hydrocortisone on the secretion of
growth factors and interleukins by normal human keratocytes and keratoconus
keratocytes in vitro.
 To determine the impact of riboflavin-UVA-PDT on viability, apoptosis,
proliferation and activation of human keratoconus keratocytes, in vitro.
 To determine the impact of crosslinking on growth factor and interleukin
secretion of human keratoconus keratocytes, in vitro
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2 MATERIALSAND METHODS
2.1 Reagents
Dulbecco's Modified Eagle Medium: (Nutrient Mixture F-12 (DMEM/F12)); fetal
bovine serum (10%); P/S (1% of 10,000 U/ml penicillin and 10 mg/ml streptomycin);
0.05% trypsin/0.02% ethylenediaminetetra-acetic acid (EDTA) were purchased from
PPA Laboratories (Pasching, Austria), Alamar blue from Invitrogen (Karlsruhe,
Germany) and propidium iodide from Molecular Probes, Inc. (Eugene, Oregon, USA).
Thyroxine and hydrocortisone were obtained from Sigma-Aldrich (Hamburg,
Germany). Collagenase A, Dispase II and Cell Proliferation ELISA-BrdU
(colorimetric) were obtained from Roche Diagnostics (Mannheim, Germany).
Fibronectin was from Sigma Chemie (Deisenhofen, Germany). The APO-DIRECTTM
Kit and all tissue culture plastics were from BD Biosciences (Heidelberg, Germany).
Mouse Anti-Human CD34-FITC was from Biozol (Eching, Germany) and Anti-alpha
smooth muscle Actin (α-SMA) antibody (FITC) was from Abcam (Cambridge, USA).
KGF was from Blue Gene Biotech (Shanghai, China), FGFb, VEGF, HGF were from
RayBiotech (Norcross, USA), IL-1β， EGF, MMP-9, MIP1α, IL-6, IL-8, TNFα were
from BD Biosciences (Heidelberg, Germany), and TGFβ1 was from Gen-Probe
Incorporated (San Diego, USA).
2.2 Isolation of primary human keratocytes
Human corneas were obtained from the Saarland University Hospital LIONS Eye
Bank and Department of Ophthalmology, Saarland University. Human keratocytes
were isolated as described previously. 79,80
In short, the human corneoscleral buttons were aseptically rinsed in phosphate-
buffered saline (PBS) before removal of the endothelium including the Descemet’s
membrane by sterile surgical disposable scalpel. A central corneal button with
epithelium was cut using a 8 mm Barron’s trephine and thereafter incubated in culture
medium containing 2.4 U/ml Dispase II for 4 hours at 37 °C. In the following, the
corneal button was washed with PBS for several times and the already loose corneal
epithelium was removed with disposable surgical scalpel. The remaining corneal
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stroma was incubated in culture medium with 1 mg/ml collagenase A for 8-10 hours
at 37 °C. The digested tissue and cells were pipetted three times and centrifuged at
800 g for 7 minutes and finally resuspended in 1 ml culture medium, which consisted
of basic medium (DMEM/F12) supplemented with 10% FBS and 1% P/S. The cell
suspension was seeded in 6-well plates and the medium was changed 24 hours after
seeding.
Medium was changed every 2 to 3 days until keratocytes reached confluence. The
cells were subcultured in 25 cm2 culture flasks after 5 to 10 days following dispersal
with 0.05 % trypsin-EDTA for 3 to 5 minutes and the passage 4 to 8 of cells was used
for experiments.
2.3 Hormone treatment
Hydrocortisone was dissolved in absolute ethanol. Final dilution was carried out in
DMEM/F-12 HAM obtaining a solution containing 20μg/ml. Thyroxine was diluted
with DMEM/F-12 HAM obtaining a solution containing 50μg/ml. These were divided
into aliquots containing the volume needed daily, kept frozen, and thawed only once
on the day of use. The doses of both hormones used in this experiment were 20μg/ml,
10μg/ml, and 1μg/ml, respectively. In order to avoid the effect of ethanol in cell
culture among different groups, contents of ethanol in each concentration of
hydrocortisone were kept the same.
Before starting hormone treatment, culture medium was replaced with DMEM/F-12
HAM with 10% FBS. Different concentrations of hormones were added, as mentioned
above, as well as cells seeded for 24 hours, and cultures were returned to the incubator
for 24 hours.
2.4 Photodynamic Therapy (PDT) of primary human keratocytes
Human keratocytes were seeded in tissue culture plates and were allowed to grow for
48 hours before photodynamic treatment. For viability, apoptosis, proliferation, CD34
and alpha-SMA expression and cytokine measurements, 0.5% and 0.1%
concentrations of riboflavin-5-phosphate were diluted in 20% Dextran-PBS. Cells
were washed with PBS once before that the above riboflavin solution was added.
Then, the cells were exposed directly to UVA light (370 nm) for 4 minutes 10 seconds
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with an irradiation dose of 8 mW/cm2 (2 J/cm2). Following illumination, cells were
washed twice with PBS, fed with culture medium and cultivated at 37 °C for
twenty-four hours before measurements.
Figure 5. Illumination box (λ = 370 nm, 2 J/cm2)
2.5 Determination of viability (phototoxicity)
Cell viability was evaluated using the Alamar blue assay as follows: Human
keratocytes or HCECs were seeded in 24-well cell culture plates at concentration of
7.5 × 103 cells/cm2 and 1.0 × 105 cells/well, respectively.
At 24 hours after illumination, Alamar blue solution was diluted with culture medium
for a final concentration of 10% and 500 µl of this solution was added to each well.
After 3 to 4 hours of incubation, 200 µl of conditioned culture medium from each well
was transferred into two wells of 96-well plates. As a negative control, Alamar blue
solution was added to a well without cells. Thereafter, all plates were exposed to an
excitation wavelength of 560 nm and the emission at 616 nm was recorded using a
Wallac 1420 Multilabel Counter (PerkinElmer Life Sciences, Wellesley, MA, USA).
2.6 Flow cytometric analysis
To determine the relative number of apoptotic cells (APO-DIRECTTM Kit), human
keratocytes or HCECs were seeded in 6-well cell culture plates with a concentration
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of 7.5 × 103 cells/cm2 and underwent PDT as described above.
They were harvested at 24 hours following PDT. First, the culture medium was
discarded and the cells were trypsinized before centrifugation. Then, the cells were
suspended in 1% paraformaldehyd at a concentration of 10 × 105 cells/ml and placed
on ice for 30-60 minutes. Thereafter, cells were washed twice with PBS and stored for
30 minutes at -20 °C following adding 1 ml ice cold 70% ethanol. After removing the
ethanol carefully by aspiration, fixed cells were resuspended twice in 1 ml
wash-buffer. The control cells and the probes were resuspended in 50 µl
DNA-labeling-solution (FITC marked dUTP) and the cells were washed twice before
resuspending the cell pellet in 500 µl PI/RNase staining buffer (0.3 ml for lower cell
amount). Cells were incubated in the dark for at least 30 minutes at room temperature
prior to analysis using a FACSCanto flow cytometer (BD Biosciences, Heidelberg,
Germany).
2.7 Determination of cell proliferation
The proliferation of the keratocytes or HCECs was determined with the cell
proliferation ELISA-BrdU kit, by the measurement of BrdU incorporation in the
newly synthesized cellular DNA. Keratocytes were plated at a density of 2 × 103
cells/well and HCECs of 5 × 103 cells/well in a 96-multiwell plate with culture
medium of 100 μl, respectively.
PDT was performed as described before with 0, 100 nM and 250 nM Ce6
concentrations. To detect the influence of PDT on the proliferation rate, we tested at
24 hours before PDT, 2 hours and 24 hours after PDT. The test was performed
according to the manufacturer’s protocol. BrdU was added to the keratocytes or
HCECs at the tissue plates and incubated at 37 °C for 4 hours (BrdU incorporation).
After removing the culture medium, the cells were fixed with FixDenat, provided with
the test kit, followed by the incubation with anti-BrdU-POD, which binds the
incorporated DNA. After adding the substrate solution, the immune complexes were
detected using an ELISA reader, Model 550 (Bio-Rad Laboratories GmbH, Munich,
Germany).
2.8 Expression of CD34 and α-SMA of keratocytes
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Cells were seeded in 6-well cell culture plates with a concentration of 4.0 × 103
cells/cm2 and underwent PDT as described above. They were harvested at 24 hours
following PDT with 0 and 100 nM of Ce6 concentration.
First, the culture medium was discarded and the cells were trypsinized and washed
with PBS. To demonstrate α-SMA, the cells were incubated with 0.5 ml PERM
solution for 10 minutes, and then the cells were washed once with PBS followed by
incubation with FITC-conjugated mouse monoclonal antibodies (IgG2a) against
human α-SMA (100 µg/104 cells) for 30 minutes in dark at room temperature. For
CD34, a FITC-conjugated monoclonal antibody (IgG1) was used directly at a
concentration of 200 µg/ml followed by an incubation step for 30 minutes in dark at
room temperature. To prove specificity of the staining, isotype control experiment for
each primary IgG-subtype antibody was performed. In a following step, all cell
preparations were washed twice with PBS and analysed using a FACSCanto flow
cytometer (BD Biosciences, Heidelberg, Germany), and the evaluation was performed
with WinMDI software (Version 2.9).
2.9 Growth factor secretion of keratocytes
Human keratocytes were seeded in 24-well cell culture plates with a concentration of
7.5×103 cells/cm2 and underwent PDT with 0 and 100 nM Ce6 concentrations. They
were harvested at five hours and twenty-four hours 24 hours following PDT.
The concentration of IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1, EGF, MIP1α, MMP-9
and TNFα in each well was measured by taking a 100 µl aliquot of the supernatant of
the wells. Measurements were performed by ELISA with the following measurement
ranges: EGF: 250-7.8 pg/mL, FGFb: 1000-8pg/mL, HGF: 8000-60 pg/mL, IL-6:
600-10 pg/mL， TGF β1: 2000-16 pg/mL, IL-1β: 1000-8 pg/mL, MMP9: 2000-16
pg/mL, TNFα: 1000-8 pg/mL, MIP1α: 500-4 pg/mL. Measured concentrations below
the above values were considered as zero. The growth factor concentrations were
quantified by using a human recombinant IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1,
EGF, MIP1α, MMP-9 and TNFα as standard. The measurements were performed
exactly following the manufactures’ ELISA-protocols. In each well, the concentration
of the growth factors in the supernatant was standardized to the cell protein
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concentration of the respective well. The absorbance was measured at 450 nm (Model
550 Bio-Rad Laboratories GmbH, München, Germany). The experiments were
repeated five times using keratocyte cultures of five donor corneas from different
patients.
After taking the supernatant for ELISA, the total protein concentration of each well
was measured following detachment of the cells with 150 µl CelLytic™ M. Protein
quantity was determined according to the method of Bradford, 80which is based on the
formation of a complex between the dye, Brilliant blue G and proteins in solution.
The absorbance was measured at 595 nm and the concentrations were quantified using
bovine serum albumin (BSA) as standard protein.
2.10 Statistical Analysis
Quantitative data were expressed as means ± standard deviation (mean ± SD).
Statistical analysis was performed using the Mann-Whitney U-test for comparisons of
the means of two independent groups. To compare data among three or more groups,
one-way analysis of variance (ANOVA) followed by the Dunnett's test was performed.
P<0.05 was considered statistically significant.
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3 RESULTS
3.1 Effects of thyroxine and hydrocortisone on human
keratocytes in normal and keratoconus corneas in vitro.
Cell proliferation of NHPK increased significantly 24h after treatment with thyroxine
from concentration of 1µg/ml and higher (p<0.01). Specifically, cell proliferation of
NHPK increased by 51%, 46%, 53% at a concentration of 1μg/ml 10μg/ml and
20μg/ml, respectively. Significant increasing of proliferation in KHPK was only
detected in 20µg/ml thyroxine group (increased by 67%) (p<0.05) (Figure 5).
Figure 5. Proliferation of NHPK and KHPK 24h after treatment with
L-thyroxine in vitro.
Cell proliferation of NHPK increased significantly 24h after treatment with 1ng/ml
FGFb (p<0.01) and 2ng/ml TGFβ1 (p<0.01), while proliferation of KHPK decreased
significantly 24h after treatment with the same concentration performed on NHPK
(p<0.01, p<0.01) (Figure 6).
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Figure 6. Proliferation of NHPK and KHPK 24h after treatment with FGFb and
TGFβ1 in vitro.
We could not detect any changes in the proliferation of both NHPK and KHPK 24h
after treatment with hydrocortisone (p>0.05). Twenty-four hours after hormone
treatment, we did not observe any changes in cell viability of NHPK and KHPK for
both thyroxine and hydrocortisone (p>0.05). Similarly, there were no changes
observed in cell apoptosis of NHPK and KHPK after treatment with thyroxine and
hydrocortisone (p>0.05) (data not shown).
3.2 Growth factor and interleukin secretion by human normal
keratocytes and keratoconus keratocytes after hormone treatment in
vitro
Cytokine secretion of normal keratocytes 5 h after hormone treatment
The mean concentration of IL-6 5 h after hormone treatment, using 10μg/mL
L-Thyroxine or 10μg/mL hydrocortisone was significantly lower than that in the
untreated group (p=0.042 and p<0.001, respectively).
The mean IL-8 concentration after incubation with 10μg/mL hydrocortisone was
significantly higher than that in the untreated group (p<0.001). However, we could not
detect any changes following treatment with 10μg/mL L-Thyroxine (p=0.336).
RESULTS 23
The mean FGFb concentration decreased after treatment with 10μg/mL
hydrocortisone (p=0.0019), whereas there were no changes detected following
treatment with 10μg/mL L-Thyroxine (p=0.22).
We could not detect any changes in the secretion of HGF or TGFβ1 at any of the
examined groups 5 h following hormone treatment, compared to untreated controls
(p>0.119).
The secretion of IL-1β, EGF, MIP1α, MMP-9 and TNFα was below the detection
limit in the treated and untreated cell cultures 5 h after treatment.
The concentrations of IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1, EGF, MIP1α, MMP-9
and TNFα secreted by normal keratocytes 5 h after hormone treatment are
summarized in Figure 7 and Table 1.
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Figure 7. Cytokine secretion of normal keratocytes 5 h after hormone treatment
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Table 1. Concentration (pg/μg protein) of different cytokines in the supernatant
of normal keratocyte cultures 5 h after hormone treatment.
Values indicate mean± SD.
* p-values indicate the difference between “Keratocytes + none L-Thyroxine” versus
“Keratocytes+ 10μg/mL L-Thyroxine” groups.
** p-values indicate the difference between “Keratocytes + none hydrocortisone”
versus “Keratocytes + 10 μg/mL hydrocortisone” groups.
Significant values are shown in bold (one-way ANOVA test).
n.d. = not detectable
n/a = not applicable
Keratocytes +
none
L-Thyroxine
Keratocytes+
10μg/mL
L-Thyroxine
Keratocytes +
none
hydrocortisone
Keratocytes +
10 μg/mL
hydrocortisone
* p-value ** p-value
IL-6 0.098±0.083 0.053±0.048 0.163±0.081 0.019±0.013 0.042 <0.001
IL-8 0.206±0.147 0.161±0.146 1.02±0.314 0.088±0.065 0.336 <0.001
FGFb 0.194±0.222 0.128±0.093 0.214±0.179 0.111±0.059 0.227 0.002
HGF 0.278±0.182 0.343±0.208 0.421±0.142 0.355±0.121 0.299 0.119
TGFβ1 0.977±0.597 0.892±0.568 1.358±0.189 1.246±0.309 0.649 0.175
IL-1β n.d. n.d. n.d. n.d. n/a n/a
EGF n.d. n.d. n.d. n.d. n/a n/a
MIP1α n.d. n.d. n.d. n.d. n/a n/a
MMP-9 n.d. n.d. n.d. n.d. n/a n/a
TNFα n.d. n.d. n.d. n.d. n/a n/a
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Cytokine secretion of keratoconus keratocytes 5 h after hormone treatment
The mean IL-6 concentration significantly increased following treatment with
10μg/mL hydrocortisone (p<0.001). However, we could not detect any changes
following treatment with 10μg/mL L-Thyroxine (p=0.949).
The mean IL-8 and TNFα concentration was significantly higher 5 h after treatment
with 10μg/mL (p=0.003 and p=0.02, respectively) and significantly lower following
treatment with 10μg/mL hydrocortisone (p=0.002 and p=0.016, respectively).
We could not detect changes in the secretion of MIP1α or TGFβ1 at any of the
examined groups 5 h following hormone treatment, compared to untreated controls
(p>0.183).
The secretion of IL-1β, EGF, FGFb, MMP-9 and HGF was below the detection
limit in the treated and untreated cell cultures 5 h after treatment.
The concentration of IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1, EGF, MIP1α, MMP-9
and TNFα secreted by keratoconus keratocytes 5 h after hormone treatment are
summarized in Figure 8 and Table 2 .
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Figure 8. Cytokine secretion of keratoconus keratocytes 5 h after hormone
treatment
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Table 2. Concentration (pg/μg protein) of different cytokines in the supernatant
of keratoconus keratocyte cultures 5 h after hormone treatment.
Values indicate mean± SD.
* p-values indicate the difference between “Keratocytes + none L-Thyroxine” versus
“Keratocytes+ 10μg/mL L-Thyroxine” groups.
** p-values indicate the difference between “Keratocytes + none hydrocortisone”
versus “Keratocytes + 10 μg/mL hydrocortisone” groups.
Significant values are shown in bold (one-way ANOVA test).
n.d. = not detectable
n/a = not applicable
Keratocytes +
none
L-Thyroxine
Keratocytes+
10μg/mL
L-Thyroxine
Keratocytes +
none
hydrocortisone
Keratocytes +
10 μg/mL
hydrocortisone
* p-value ** p-value
IL-6 0.249±0.236 0.253±0.152 0.31±0.193 0.042±0.038 0.949 <0.001
IL-8 0.592±0.279 0.943±0.418 0.359±0.24 0.168±0.09 0.003 0.002
TNFα 0.158±0.11 0.276±0.188 0.298±0.182 0.174±0.126 0.02 0.016
MIP1α 0.179±0.102 0.227±0.127 0.251±0.158 0.189±0.125 0.2 0.183
TGFβ1 1.94±0.94 2.07±0.91 2.68±1.045 2.392±0.965 0.669 0.371
FGFb n.d. n.d. n.d. n.d. n/a n/a
HGF n.d. n.d. n.d. n.d. n/a n/a
EGF n.d. n.d. n.d. n.d. n/a n/a
IL-1β n.d. n.d. n.d. n.d. n/a n/a
MMP-9 n.d. n.d. n.d. n.d. n/a n/a
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Cytokine secretion of normal keratocytes 24 h after hormone treatment
The mean IL-6, IL-8, EGF and TGFβ1 concentration was significantly decreased
after treatment with 10μg/mL hydrocortisone (p<0.001, p=0.017, p=0.02 and p=0.019,
respectively), whereas no changes were observed following treatment with 10μg/mL
L-Thyroxine (p=0.736, p=0.301, p=0.297 and p=0.651, respectively).
The mean HGF concentration after treatment with 10μg/mL L-Thyroxine, was
significantly increased (p=0.038), while there were no changes following treatment
with 10μg/mL hydrocortisone (p=0.783).
We could not detect changes in the secretion of TNFα at any of the examined groups
24 h following hormone treatment, compared to untreated controls (p>0.534).
The secretion of IL-1β, MIP1α, MMP-9 and FGFb was below the detection limit in
the treated and untreated cell cultures 24 h after treatment.
The concentrations of IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1, EGF, MIP1α, MMP-9
and TNFα secreted by normal keratocytes 24 h after hormone treatment are
summarized in Figure 9 and Table 3.
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Figure 9. Cytokine secretion of normal keratocytes 24 h after hormone treatment
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Table 3. Concentration (pg/μg protein) of different cytokines in the supernatant
of normal keratocyte cultures 24 h after hormone treatment.
Values indicate mean± SD.
* p-values indicate the difference between “Keratocytes + none L-Thyroxine” versus
“Keratocytes+ 10μg/mL L-Thyroxine” groups.
** p-values indicate the difference between “Keratocytes + none hydrocortisone”
versus “Keratocytes + 10 μg/mL hydrocortisone” groups.
Significant values are shown in bold (one-way ANOVA test).
n.d. = not detectable
n/a = not applicable
Keratocytes +
none
L-Thyroxine
Keratocytes+
10μg/mL
L-Thyroxine
Keratocytes +
none
hydrocortisone
Keratocytes +
10 μg/mL
hydrocortisone
* p-value ** p-value
IL-6 0.24±0.177 0.182±0.183 0.543±0.198 0.122±0.089 0.301 <0.001
IL-8 1.228±0.648 1.158±0.664 1.941±0.446 1.648±0.272 0.736 0.017
EGF 0.057±0.041 0.045±0.027 0.102±0.039 0.073±0.036 0.297 0.02
TGFβ1 1.229±0.864 1.114±0.725 2.076±0.522 1.718±0.388 0.651 0.019
HGF 1.433±0.919 2.119±1.087 2.036±1.236 2.136±1.022 0.038 0.783
TNFα 0.248±0.196 0.223±0.191 0.384±0.234 0.335±0.255 0.679 0.534
FGFb n.d. n.d. n.d. n.d. n/a n/a
MIP1α n.d. n.d. n.d. n.d. n/a n/a
IL-1β n.d. n.d. n.d. n.d. n/a n/a
MMP-9 n.d. n.d. n.d. n.d. n/a n/a
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Cytokine secretion of keratoconus keratocytes 24 h after hormone treatment
The mean IL-6 and TGFβ1 concentration was significantly decreased 24 h following
treatment with 10μg/mL hydrocortisone (p<0.001 and p<0.001, respectively), whereas
there were no changes observed after treatment with 10μg/mL L-Thyroxine (p=0.433
and p=0.955, respectively).
The mean HGF concentration was significantly increased after treatment with
10μg/mL L-Thyroxine (p=0.005), and decreased after treatment with 10μg/mL
hydrocortisone ( p<0.001).
We could not detect changes in the secretion of IL-8 or TNFα at any of the examined
groups 24 h following hormone treatment, compared to untreated controls (p>0.417).
The secretion of IL-1β, MIP1α, MMP-9, EGF and FGFb was below the detection
limit in the treated and untreated cell cultures 24h after treatment.
The concentrations of IL-1β, IL-6, IL-8, FGFb, HGF, TGFβ1, EGF, MIP1α, MMP-9
and TNFα secreted by keratoconus keratocytes 24 h after hormone treatment are
summarized in Figure 10 and Table 4.
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Figure 10. Cytokine secretion of keratoconus keratocytes 24 h after hormone
treatment
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Table 4. Concentration (pg/μg protein) of different cytokines in the supernatant
of keratoconus keratocyte cultures 24 h after hormone treatment.
Values indicate mean± SD.
* p-values indicate the difference between “Keratocytes + none L-Thyroxine” versus
“Keratocytes+ 10μg/mL L-Thyroxine” groups.
** p-values indicate the difference between “Keratocytes + none hydrocortisone”
versus “Keratocytes + 10 μg/mL hydrocortisone” groups.
Significant values are shown in bold (one-way ANOVA test).
n.d. = not detectable
n/a = not applicable
Keratocytes +
none
L-Thyroxine
Keratocytes+
10μg/mL
L-Thyroxine
Keratocytes +
none
hydrocortisone
Keratocytes +
10 μg/mL
hydrocortisone
* p-value ** p-value
IL-6 0.387±0.368 0.308±0.252 0.777±0.476 0.081±0.088 0.433 <0.001
TGFβ1 3.317±1.894 3.347±1.431 4.693±1.46 2.355±1.075 0.955 <0.001
HGF 1.007±0.604 1.889±1.184 0.522±0.498 1.637±1.173 0.005 <0.001
IL-8 4.73±2.616 4.141±1.854 3.726±1.955 3.298±1.905 0.417 0.487
TNFα 0.44±0.353 0.409±0.397 0.424±0.37 0.379±0.373 0.799 0.783
EGF n.d. n.d. n.d. n.d. n/a n/a
FGFb n.d. n.d. n.d. n.d. n/a n/a
MIP1α n.d. n.d. n.d. n.d. n/a n/a
IL-1β n.d. n.d. n.d. n.d. n/a n/a
MMP-9 n.d. n.d. n.d. n.d. n/a n/a
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3.3 Viability, apoptosis, proliferation and activation of human
keratoconus keratocytes after crosslinking/
riboflavin-UVA-photodynamic therapy (PDT)
KC keratocyte viability
Results of the alamarBlue® assay are shown in Figure 11 (n=5). With the separate
use of riboflavin or UVA-light illumination, viability of KC keratocytes did not
change significantly compared to controls (p>0.34). Following riboflavin-UVA-PDT,
using 0.1% riboflavin , KC keratocyte viability was significantly decreased (p=0.047),
compared to controls.
Figure 11. Viability of human KC keratocytes 24 hours following PDT.
KC keratocyte apoptosis
Figure 12 shows the percentage of apoptotic KC keratocytes 24 hours following
crosslinking (n=5). Using the APO-DIRECTTM kit, there was no significant difference
in the percentage of apoptotic KC keratocytes using riboflavin or UVA-light
illumination separately (p>0.26). However, using riboflavin-UVA-PDT, with 0.05%
or 0.1% riboflavin, significantly increased the percentage of apoptotic KC keratocytes
compared to controls (p=0.025 and p=0.01 respectively).
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Figure 12. Percentage of apoptotic KC keratocytes 24 hours following PDT.
KC keratocyte proliferation
Proliferation of KC keratocytes is displayed in Figure 13 (n=5). Using riboflavin or
UVA light illumination separately, proliferation of KC keratocytes did not change
significantly (p>0.25). Twenty-four hours after PDT, proliferation of KC keratocytes
was inhibited significantly using 0.05% or 0.1% riboflavin concentrations (p=0.009
for both concentrations) compared to controls.
RESULTS 37
Figure 13. Proliferation of human KC keratocytes 24 hours after PDT.
CD34 expression of KC keratocytes
CD34 expression of KC keratocytes twenty-four hours following PDT is summarized
in Figure 14 (n=5). Using riboflavin, illumination only or using riboflavin-UVA-PDT
resulted in no significant change in CD34 expression compared to controls (p>0.15).
Figure 14. CD34 expression of keratoconus keratocytes 24 hours after PDT.
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Alpha-SMA expression of KC keratocytes
Alpha-SMA expression in KC keratocytes twenty-four hours following PDT is
summarized in Figure 15 (n=5). There was no significant difference in the percentage
of alpha-SMA positive KC keratocytes using riboflavin or UVA-light illumination
separately (p>0.16). Using riboflavin-UVA-PDT, there was also no significant
difference at 0.05% or 0.1% riboflavin (p=0.15 and p=0.06, respectively) in
alpha-SMA expression in keratocytes compared to controls.
Figure 15. α-SMA expression of KC keratocytes 24 hours after PDT.
3.4 Growth factor and interleukin secretion of human
keratoconus keratocytes after crosslinking /
riboflavin-UVA-photodynamic treatment (PDT)
Growth factors secretions 5 hours after crosslinking
GFb, KGF, VEGF, HGF and TGFβ1 concentrations 5 hours after crosslinking are
summarized in Figure 16 and Table 5. The secretion of KGF was below the detection
limit in the treated and untreated cell cultures 5 hours after treatment. With the
separate use of riboflavin or UVA-light illumination, growth factor and interleukin
secretion of keratoconus keratocytes did not differ significantly from untreated
controls (p>0.34, p>0.08). Using 0.1% riboflavin and illumination, the mean FGFb
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concentration was 6.32 ± 1.84 pg/ μg protein in the supernatant of the medium of KC
keratocytes. This was significantly higher than FGFb concentration in untreated KC
keratocyte cultures (3.28 ± 2.40 pg/μg protein; p=0.037). We could not detect changes
in the secretion of VEGF, HGF, or TGFβ1 of KC keratocytes at any of the examined
groups 5 hours following crosslinking, compared to controls (p>0.35).
Figure 16. FGFb, HGF, TGFβ1 and VEGF secretion of keratocytes (mean pg/μg
protein ± SD) 5 hours following crosslinking.
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Table 5. Concentration (pg/μg protein) of different growth factors in the supernatant
of keratoconus keratocyte cultures 5 hours after crosslinking. Values indicate mean±
SD.
* p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin” groups.
** p-values indicate the difference between “Keratocytes” versus “Keratocytes + 370
nm” groups.
*** p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin + 370 nm” groups.
Significant values are shown in bold (Mann-Whitney U test).
n.d. = not detectable
n/a = not applicable
Interleukins secretions 5 hours after corsslinking
IL-1β, IL-6 and IL-8 concentrations 5 hours after crosslinking are summarized in
Figure 17 and Table 6. The secretion of IL-1β was below the detection limit in the
treated and untreated cell cultures 5 hours after treatment. With the separate use of
riboflavin or UVA-light illumination, growth factor and interleukin secretion of
keratoconus keratocytes did not differ significantly from untreated controls (p>0.47,
p>0.47). We could not detect changes in the secretion of IL-6, or IL-8 of KC
keratocytes at any of the examined groups 5 hours following crosslinking, compared
to controls (p>0.35).
Keratocytes Keratocytes+ riboflavin
Keratocytes
+ 370nm
Keratocytes
+ riboflavin
+ 370nm
*
p-value
**
p-value
***
p-value
FGFb 3.28±2.40 3.89±1.15 3.10±1.06 6.32±1.84 0.34 0.6 0.037
HGF 1.73±0.58 1.74±0.45 1.79±0.36 1.83±0.48 0.92 0.6 0.75
TGFβ1 3.19±0.76 3.48±.58 3.09±0.61 3.51±0.57 0.47 0.75 0.35
VEGF 2.79±0.07 3.13±1.04 2.24±0.75 2.55±1.05 0.75 0.08 0.35
KGF n.d. n.d. n.d. n.d. n/a n/a n/a
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Figure 17. IL-6 and IL-8 secretion of keratocytes (mean pg/μg protein ± SD) 5
hours following crosslinking.
Table 6. Concentration (pg/μg protein) of different interleukins in the supernatant of
keratoconus keratocyte cultures 5 hours after crosslinking. Values indicate mean± SD.
* p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin” groups.
** p-values indicate the difference between “Keratocytes” versus “Keratocytes + 370
nm” groups.
*** p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin + 370 nm” groups.
Significant values are shown in bold (Mann-Whitney U test).
n.d. = not detectable
n/a = not applicable
Keratocytes Keratocytes+ riboflavin
Keratocytes
+ 370nm
Keratocytes
+ riboflavin
+ 370nm
* p-value ** p-value *** p-value
IL-1β n.d. n.d. n.d. n.d. n/a n/a n/a
IL-6 0.13±0.08 0.15±0.08 0.14±0.06 0.11±0.04 0.47 0.47 0.35
IL-8 0.91±0.36 1.01±0.34 0.89±0.4 0.87±0.37 0.6 0.47 0.92
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Growth factors secretions 24 hours after crosslinking
Figure 18 and Table 7 display FGFb, KGF, VEGF, HGF and TGFβ1 concentrations
24 hours after crosslinking. KGF secretion was below the detection limit in the treated
and untreated cell cultures 24 hours after crosslinking. With the separate use of
riboflavin or UVA-light illumination, growth factor and interleukin secretion of
keratoconus keratocytes did not change significantly compared to controls (p>0.12,
p>0.35). 24 hours after crosslinking, FGFb, VEGF, HGF and TGFβ1 secretion also
did not change significantly compared to untreated control KC keratocyte cultures
(p>0.12).
Figure 18. FGFb, HGF, TGFβ1 and VEGF secretion of keratocytes (mean pg/μg
protein ± SD) 24 hours following crosslinking.
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Table 7. Concentration (pg/μg protein) of different cytokines in the supernatant of
keratoconus keratocyte cultures 24 hours after crosslinking. Values indicate mean±
SD.
* p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin” groups.
** p-values indicate the difference between “Keratocytes” versus “Keratocytes + 370
nm” groups.
*** p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin + 370 nm” groups.
Significant values are shown in bold (Mann-Whitney U test).
n.d. = not detectable
n/a = not applicable
Interleukins secretions 24 hours after crosslinking
Figure 19 and Table 8 display IL-1β, IL-6 and IL-8 concentrations 24 hours after
crosslinking. IL-1β secretion was below the detection limit in the treated and
untreated cell cultures 24 hours after crosslinking. With the separate use of riboflavin
or UVA-light illumination, growth factor and interleukin secretion of keratoconus
keratocytes did not change significantly compared to controls (p>0.47, p>0.6). 24
hours after crosslinking, IL-6 and IL-8 secretion also did not change significantly
compared to untreated control KC keratocyte cultures (p>0.35).
Keratocytes Keratocytes+ riboflavin
Keratocytes
+ 370nm
Keratocytes
+ riboflavin
+ 370nm
* p-value ** p-value *** p-value
FGFb 1.1±0.36 2.26±1.3 1.09±0.36 2.88±2.53 0.12 0.75 0.3
HGF 3.94±0.8 4.39±0.77 3.72±0.26 4.28±0.71 0.35 0.35 0.6
TGFβ1 4.66±0.1 4.62±0.46 4.62±0.4 4.43±0.44 0.6 0.92 0.12
VEGF 12.75±2.01 16.02±4.82 11.7±2.47 14.92±3.8 0.18 0.35 0.25
KGF n.d. n.d. n.d. n.d. n/a n/a n/a
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Figure 19. IL-6 and IL-8 secretion of keratocytes (mean pg/μg protein ± SD) 24
hours following crosslinking.
Table 8. Concentration (pg/μg protein) of different cytokines in the supernatant of
keratoconus keratocyte cultures 24 hours after crosslinking. Values indicate mean±
SD.
* p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin” groups.
** p-values indicate the difference between “Keratocytes” versus “Keratocytes + 370
nm” groups.
*** p-values indicate the difference between “Keratocytes” versus “Keratocytes +
Riboflavin + 370 nm” groups.
Significant values are shown in bold (Mann-Whitney U test).
n.d. = not detectable
n/a = not applicable
Keratocytes Keratocytes+ riboflavin
Keratocytes
+ 370nm
Keratocytes
+ riboflavin
+ 370nm
* p-value ** p-value *** p-value
IL-1β n.d. n.d. n.d. n.d. n/a n/a n/a
IL-6 0.31±0.16 0.45±0.26 0.29±0.17 0.37±0.15 0.53 0.6 0.75
IL-8 8.95±2.64 8.11±2.41 9.43±2.79 7.52±1.59 0.47 0.92 0.35
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4 DISCUSSION
4.1 Effects of thyroxine and hydrocortisone on human
keratocytes in normal and keratoconus corneas in vitro.
The potential clinical association between corneal ectatic disease and thyroid gland
dysfunction has been known for several decades. Clinical observations of
hypothyroidism in patients with keratoconus were first reported by Appelbaum in
mid-1930’s. 81 King subsequently reported the appearance of keratoconus following
thyroidectomy. 4 Lang et al. described a case of Alagille syndrome with keratoconus
and secondary hypothyroidism. 82 More recently, Kocak et al. reported a case of
bilateral keratoconus associated with Hashimoto’s disease. 83
The implication of thyroid hormones in corneal embryogenesis and physiology is of
paramount importance, since it is well-established that thyroid hormones play a
crucial role in corneal dehydration and transparency during embryonic development.
33Conrad et al. have reported the presence of thyroxine receptors alpha and beta in the
chicken cornea, 34 while our research group has recently documented the expression
of thyroxin receptors in human cornea (data under review). Moreover, thyroid
hormonal changes and female sex hormones affect distinctly ocular physiology and
pathophysiology during pregnancy. 84-92 This has been highlighted by recent case
reports of keratoconic progression, with development of acute corneal hydrops,
induced by thyroxinemia during pregnancy 3 and pregnancy-associated exacerbation
of iatrogenic ectasia. 86,87
Kahan et al. were the first to show that tear thyroxine levels in patients with
keratoconus, independently of their thyroid function, were 2-50 times higher than that
of normal subjects. 5 They found that tear thyroxine levels were higher during the
progression of keratoconus and declined once the cornea1 curvature reached a new
steady value.
At a molecular level, thyroxine functions as a transcription regulator, binding to
nuclear thyroxine receptors α (THRα) and β (THRβ), which bind DNA thyroxine
receptor response elements (TREs) and recruit either corepressor coactivator
complexes that subsequently repress or activate target gene transcription. 93
DISCUSSION 46
Conrad et al. documented that all corneal layers of the chick cornea express THRA
mRNA, while keratocytes and endothelial cells alone express THRB mRNA. 34
During normal development, THRB expression increases 20-fold from embryonic day
12 to embryonic day 20, whereas THRA expression remains constant. 34 Exposure of
chicken embryonic corneas to thyroxine in vitro affected significantly the expression
of corneal transparency-associated genes, which control the keratan sulfate
proteoglycan (KSPG) synthesis and the production of crystallins. 33
Xie et al. demonstrated that the functional expression of Toll-like receptors-2 and -4 in
human corneal epithelial cells is enhanced in vitro by low-concentration
hydrocortisone. 94 Toll-like receptors (TLRs) play an essential role in triggering the
innate immune response by recognizing pathogen-associated molecular patterns and
stimulating the activity of host immune cells against several microbial products. 95 It
has been well established that TLR are expressed on human corneal epithelium and
play an important role in cornea protection against microbial infection. 96
In our study, we investigated the effect of thyroxine and hydrocortisone on normal and
keratoconus human corneal keratocytes in vitro. Exposure to thyroxine significantly
increased the proliferation of normal keratocytes. Proliferation of keratoconus
keratocytes only increased after treatment with very high thyroxine concentrations.
Interestingly, we discovered that TGFβ1 and FGFb, which stimulate the proliferation
of NHPK, induced decreased proliferation of KHPK. Ley et al. reported that FGFb
acts in autocrine and paracrine manner to stimulate corneal fibroplasias, 97 while
Maier et al. showed that active TGFβ is increased in the aqueous humor of
keratoconus patients. 98Considering the effect of TGFβ1 and FGFb on KHPK in vitro,
we assume that KHPK may have reduced proliferation potential compared to NHPK
due to the altered corneal homeostasis in keratoconus, which may lead to expression
of abnormal receptors for thyroxine, TGFβ1 and FGFb by the keratoconus keratocytes.
These abnormal receptors may be inactive or present different features compared to
those expressed by normal keratocytes. However, further research is required in
order to confirm this working hypothesis.
Treatment with hydrocortisone in vitro did not significantly affect the cell
proliferation of both normal and keratoconus keratocytes. Neither of the two
hormones induced any significant changes in cell viability and/or cell apoptosis in
normal or keratoconus keratocytes. These results suggest that thyroxine may play an
important role in the cell metabolism of human corneal keratocytes in the normal
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cornea, thereby explaining to some extent the reported corneal biomechanical
variations induced by thyroid hormone changes. Keratoconus keratocytes appear to
have reduced proliferation potential and this finding could be associated with the
altered corneal homeostasis in keratoconus. Further studies are required in order to
delineate the complex mechanisms of hormonal influences on corneal cell physiology
and homeostasis, especially in keratoconus.
4.2 Growth factor and interleukin secretion by human normal
keratocytes and keratoconus keratocytes after hormone treatment in
vitro
Although keratoconus has primarily been described as a non-inflammatory disease,
there is increasing evidence that immunological and inflammatory processes are
playing a role in its pathophysiology. 6-8 The association between keratoconus and
allergy, 99,100 as well as the role played by eye rubbing in the development of corneal
ectatic disease, is well established. 101,102 Eye rubbing may contribute to the
development of keratoconus by activating inflammatory mediators, more so than by
the physical pressure applied to the eyeball. 103 Indeed, IL-1 has been implicated as a
mediator of keratoconus in eye patients presenting excessive eye rubbing. 7Moreover,
patients with keratoconus demonstrate increased levels of inflammatory molecules in
the tear film and the concentration of these agents has been associated with the
severity of keratoconus. 8,104
Keratocytes are the major cell type of the corneal stroma, and they contribute to the
local inflammatory response by releasing various chemokines, such IL-1β, L-6, and
IL-8. 105 IL-1β plays a crucial role in corneal wound healing and it is able to induce the
expression of keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF)
by corneal keratocytes, thereby regulating the proliferation, motility, and
differentiation of corneal epithelial cells following corneal surface injury. 106 IL-6 and
IL-8 are important mediators of inflammatory cell response in the cornea, and are
secreted in response to inflammatory stimulus. 107 IL-6 secretion by corneal
keratocytes is induced following trauma or infection by IL-1α and TNFα, secreted
from corneal epithelial cells. 108 IL-8 is a pro-inflammatory cytokine, produced by
corneal keratocytes, which plays an important role in inflammation and wound
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healing. 109,110 IL-8 has the capacity to recruit T-cells as well as nonspecific
inflammatory cells into sites of inflammation by activating neutrophils. 111
Furthermore, IL-8 is chemotactic for fibroblasts and accelerates their migration and
can stimulate deposition of tenascin, fibronectin, and collagen I during wound healing
in vivo. 112 Both human corneal keratocytes and epithelial cells have been shown to
synthesize and release IL-8 following cytokine stimulation and/or infection. 113,114
On the other hand, fibroblast growth factor basic (FGFb), epidermal growth factor
(EGF), hepatocyte growth factor (HGF) and transforming growth factor-β1 (TGFβ1)
represent important mediators of corneal stromal-epithelial interactions and they are
involved in corneal wound healing. 115-118 Furthermore, TGFβ1 is involved in
inflammatory reaction and induces myofibroblast differentiation, while FGFb
promotes angiogenesis, cell proliferation and migration, inducing the differentiation
of keratocytes into a fibroblastic phenotype. 119 HGF delays the process of
re-epithelialization, induces myofibroblastic transformation of keratocytes, while it
also has an inhibitory effect on cell apoptosis. 120,121
The aim of this study was to evaluate the effect of thyroxine and hydrocortisone on
the secretion of growth factors and interleukins by normal human keratocytes and
keratoconus keratocytes in vitro. It is has been reported that all corneal layers in
chicken cornea express thyroxine receptor alpha (TRA) mRNA, while keratocytes and
endothelial cells express thyroxine receptors beta (TRB) mRNA. 111 During normal
development TRA expression increases 20-fold from embryonic day 12 to embryonic
day 20, whereas TRB expression remains stable. 122 Interestingly, treatment with
thyroxine modifies the synthesis of keratan sulfate proteoglycan and modulates the
expression of carbonic anhydrase genes in chicken cornea. 122 Our research group
discovered that normal human keratocytes also express thyroxine receptors, which
demonstrate significant alteration in their expression in keratoconus (data under
review). Moreover, it has been documented that hydrocortisone down-regulates the
expression of Toll-like receptor-2 and -4 by corneal keratocytes in vitro, 46 thereby
modulating the innate corneal immune system, since Toll-like receptors stimulate the
pro-inflammatory cytokines and chemokines, such as TNF-α, IL-6, IL-8, IL-18, and
monocyte chemotactic protein-1. 47,48 The release of IL-6 and IL-8 is inhibited by
hydrocortisone in vitro. 49
In our study, we have shown that treatment with thyroxine significantly
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downregulates the secretion of IL-6 by normal keratocytes in vitro, but it upregulates
the secretion of IL-8 and TNFa by keratoconus keratocytes in vitro. These results
suggest that thyroxine inhibits the inflammatory response in normal cornea in vitro,
while it promotes the inflammation process in keratoconus cornea in vitro. We have
recently discovered that thyroxine stimulates the proliferation of normal human
keratocytes in vitro, while the proliferation potential of keratoconus keratocytes is
significantly reduced (data under review). We have assumed that modified expression
of the corneal thyroxine receptors occurring in keratoconus (data under review) may
account for the observed differences in keratocyte proliferation. Differentiated
expression of thyroxine receptors by corneal keratocytes as well as alteration in
corneal homeostasis may also contribute to the different effect of thyroxine on
interleukins in normal and keratoconus cornea in vitro.
On the other hand, treatment with hydrocortisone significantly down-regulates the
secretion of IL-6, IL-8, FGFb, EGF and TGFβ1 by normal keratocytes in vitro, while
it also down-regulates the secretion of IL-6, IL-8, TNFa and TGFβ1 by keratoconus
keratocytes in vitro. These results are in agreement with other studies reporting that
hydrocortisone inhibits the release of IL-6 and IL-8, decreasing the impact of the
inflammatory cascade. 47-49 Moreover, we observed that hydrocortisone
down-regulates the production of growth factors, which induce angiogenesis and
differentiation of keratocytes into myofibroblasts, thereby playing a significant role in
corneal wound healing.
Our results suggest that hormonal influences may modulate the secretion of
interleukins and growth factors by human corneal keratocytes in vitro, thereby
affecting the inflammatory response in corneal stroma. The effects are different in
normal and keratoconus keratocytes, which may reflect the alteration of receptors
expression by corneal keratocytes in keratoconus. Further studies are required in order
to delineate the pathophysiological mechanisms underlying the hormonal modulation
of inflammatory response mediated by human corneal keratocytes.
4.3 Viability, apoptosis, proliferation and activation of human
keratoconus keratocytes after crosslinking/
riboflavin-UVA-photodynamic therapy (PDT)
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Corneal collagen crosslinking was first introduced by Wollensak, Spoerl and Seiler to
inhibit or stop disease progression and to increase the biomechanical stability of the
cornea in KC. 9 It has been documented that crosslinking flattens keratometric
readings, reduces cone progression and even improves best corrected visual acuity.
123,124
Although crosslinking is in clinical use, to the best of our knowledge, the impact of
crosslinking on KC keratocytes has not yet been analysed in detail.
The present study showed that in human KC keratocytes viability decreases, apoptosis
is triggered and proliferation is inhibited, however multipotent haematopoietic stem
cell transformation and myofibroblastic transformation remains unchanged 24 hours
after treatment.
Viability and apoptosis of normal keratocytes have been analysed by several authors
following crosslining in the past: Wollensak et al. have shown an abrupt cytotoxic
effect in vitro on normal porcine keratocytes and Grobe et al. detected significantly
decreased cell viability in a human keratocyte cell line. 126,127 Recently, our research
group has shown that crosslinking decreases viability, however this does not have an
impact on apoptosis of primary normal human keratocytes in vitro. Interestingly, in
primary human KC keratocytes our present study revealed the triggering of apoptosis
24 hours after crosslinking treatment.
Kim et al. and Kaldawy et al. described that an increased percentage of apoptotic
keratocytes is present in human KC corneas compared to normal human controls. 128
Macé et al. suggested that cell loss resulting from antiproliferative and hyperapoptotic
phenotypes may be responsible for the pathogenesis of KC. 129 In addition, changes in
corneal protein pattern, increase in enzymatic activities and cell apoptosis are also
thought to be part of KC progression. 130 Chwa et al. described an increased basal
generation of reactive oxygen species and reactive nitrogen species in KC
keratocytes.131
Five to 30 months following crosslinking therapy, Messmer et al. described keratocyte
damage, increased antiapoptitic bax and/or antiapoptotic surviving protein expression
in keratocytes compared to untreated KC controls. 132 In our opinion, the programmed
cell death of keratocytes has to be further analysed at the cellular-subcellular level,
alterations of the apoptotic pathways in normal and KC keratocytes have to be
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described (also following crosslinking), so that we are better able to understand the
disease.
The decreased proliferation of KC keratocytes 24 hours after crosslinking in our
present study is not in accordance with the published in vivo results six months after
treatment, which have shown an increased proliferation (Ki67 positivity) of the cells
at this time point. 133 In our opinion the triggered proliferation at six months after
CXL is part of the late wound healing response and proliferation after 24 hours is
likely to be also inhibited in vivo. Our previous study also reported on decreased
proliferation of primary human keratocytes 24 hours following chlorine e6
photodynamic therapy in accordance with our present riboflavin-PDT results. 134
CD34 positive keratocytes are confirmed to be multipotent haemopoetic stem cells
which may play a role in cytoadhesion and signaling related to differentiation and
proliferation. 135-137 Meanwhile, α-SMA is agreed to be a marker of myofibroblasts.
Corneal myofibroblasts synthesize and secrete collagen I and play an important role in
wound healing and contraction. 136 Furthermore, recent studies revealed that by
expressing toll-like receptor (TLR), corneal myofibroblasts may take part in pathogen
clearance. 136 It is also suggested that myofibroblast differentiation down-regulates
keratocyte CD34 expression. 138
Several authors reported on the occurrence of early bacterial or acanthamoeba
keratitis after corneal crosslinking. Our previous study found induced myofibroblastic
transformation and multipotent haematopoietic stem cell transformation in normal
human keratocytes 24 hours after CXL. 139 These results do not support the hypothesis
that CXL suppresses the inflammatory response of keratocytes, which leads to an
increased incidence of infectious keratitis after CXL. In contrast, the inflammatory
response should be promoted through CXL.
Most interestingly, in human KC keratocytes, CD34 and α-SMA expression remained
unchanged following CXL. In other words, the percentage of multipotent
haemopoetic stem cells and myofibroblasts remained unchanged after treatment,
compared to untreated KC keratocytes. Therefore, we also do not see an increased risk
of infectious keratitis in KC patients after crosslinking. At least this should not be
correlated with intraoperative modification of the cellular response.
In summary, crosslinking/riboflavin-UVA-photodynamic-inactivation decreases
viability, triggers apoptosis and inhibits proliferation, however it does not have an
impact on multipotent haematopoietic stem cell transformation and myofibroblastic
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transformation of human KC keratocytes in vitro. We oppose the idea that
crosslinking may induce bacterial or acanthamoeba keratitis. Alterations of
intracellular pathways following crosslinking have to be further analysed in the future.
4.4 Growth factor and interleukin secretion of human
keratoconus keratocytes after crosslinking /
riboflavin-UVA-photodynamic treatment (PDT)
The present study determined that CXL triggers FGFb secretion of keratocytes
transiently (5 h). In the short term, CXL does not have an impact on HGF, TGFβ1,
VEGF, KGF, IL-1β, IL-6, and IL-8 secretion of KC keratocytes, in vitro.
FGF promotes angiogenesis, cell proliferation and migration and also induces the
differentiation of keratocytes into a fibroblastic phenotype. 141 In accordance with that
there was no impact of CXL on myofibroblastic transformation and multipotent
haemopoetic stem cell transformation of keratoconus keratocytes in our recent study.
In contrast, with decreased FGFb secretion after CXL in normal keratocytes, both
(normal and KC) keratocyte forms were activated after treatment. Ley at al. described
that ultraviolet light induces FGFb, due to DNA damage. 97 In accordance with that
we saw an increased FGFb secretion after CXL and also induced apoptosis of KC
keratocytes in a former study. In addition, FGFb secretion was decreased in normal
keratocytes 5 and 24 h following CXL and we could not detect triggered apoptosis of
these cells following CXL. 142,143
It is known that HGF and TGFβ1 induce myofibroblastic transformation of
keratocytes. Our present results with stable HGF and TGFβ1 secretion of the cells 5
and 24 h after treatment also were in accordance with results of our previous studies:
there was no significant impact of CXL on myofibroblastic transformation or
multipotent haemopoetic stem cell transformation of keratoconus keratocytes. 142,143
HGF and KGF are secreted through the stromal cells of the cornea and are known to
inhibit the process of epithelialization. 144-146 With unchanged HGF and KGF secretion
of keratoconus keratocytes following CXL, we do not expect an impact of CXL on
corneal epithelial proliferation or migration. Interestingly, in our previous work on
normal keratocytes after CXL, both HGF and KGF were down-regulated. The
response of different keratocyte cell types on CXL should be further analysed. 142,143
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Lee et al. reported on the inhibitory effect of HGF on apoptosis of the cells. We
demonstrated that in normal keratocytes higher concentration of HGF (compared to
our present study) after CXL prevented keratocytes from apoptosis. 149 In contrast, in
our present study, a relative lower HGF secretion of KC keratocytes might be related
to triggered apoptosis. 142,143
Interestingly, in our recent study, 5 h after CXL of normal keratocytes, VEGF
secretion was significantly decreased, which indicates that in normal cells
riboflavin-UVA-PDT may inhibit haemangiogenesis and lymphangiogenesis in the
short term. In contrast, in our present study we verified no changes in VEGF secretion
of keratoconus keratocytes following crosslinking. Therefore, CXL may not have an
impact on corneal haemangiogenesis and lymphangiogenesis in keratoconus patients
in the short term. 143
Konstantopoulos, Hirano and Kick reported of IL-1β, IL-6 and IL-8 as the key
cytokines in corneal inflammation. 148-152 These cytokines were shown to be
chemotactic for riboflavin in infected corneal cells, which can cause corneal
destruction. Previously we detected significantly increased IL-6 secretion in normal
keratocytes after CXL, however in our present study on keratoconus keratocytes, IL-6
and IL-8 secretion did not change significantly after treatment. Therefore, we do not
expect an impact of CXL on the inflammatory response of keratoconus patients, but
we do expect a positive effect of the treatment (chemotactic for riboflavin) in
non-keratoconic corneas, e.g. with infectious keratitis.
IL-1 is a key factor in the corneal wound healing cascade, which leads to keratocyte
apoptosis and/or necrosis after epithelial injury and the effect appears to be mediated
via the Fas/Fas ligand system. 153-155 In the present research, IL-1 was not detected in
the supernatant of KC keratocytes, but it was present in normal keratocyte cultures. 144
This indicates that IL-1 does not seem to play a key role in the wound healing cascade
after CXL, at least in vitro.
Oleinick et al have reported that IL-6-induced apoptosis is an important mode of
photodynamic therapy induced cell death. 156 Furthermore, in a research with IL-6
transfected cells, apoptotic response was suggested to occur by induction of IL-6
expression which activates bax and bcl-2 after photodynamic therapy. 157 In our
present study, IL-6 remained unchanged after PDT in KC keratocytes, however, it was
down-regulated in normal keratocytes in a previous study. 142
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In keratoconus keratocytes we detected triggered apoptosis after crosslinking in a
previous study and in the same time an increased apoptosis supporting FGFb and
unchanged apoptosis triggering IL-1 and IL-6 secretion and unchanged apoptosis
inhibiting HGF secretion. 142,157 The stimulus of cytokins on the apoptotic pathways of
different keratoctye types after CXL has to be further clarified.
In conclusion, crosslinking triggers FGFb secretion of keratoconus keratocytes
transiently (5 h), which normalizes after 24 h. Crosslinking does not seem to have an
impact on HGF, TGFβ1, VEGF, KGF, IL-1β, IL-6, and IL-8 secretion of keratoconus
keratocytes in the short term.
Growth factor and interleukin secretion of normal and keratoconus keratocytes differs
after crosslinking, dependent on the response of keratocytes (activation or apoptotis)
to the treatment in both conditions (normal and KC keratocytes). Alterations of the
intracellular pathways after crosslinking have to be further analyzed in the future.
4.5 Conclusions and outlook to the future
In our work we showed that, keratoconus and normal keratocytes are different in
proliferation potential and inflammation responding to exposure of thyroxine.
Hydrocortisone decreases the inflammatory cascade of both cell types. Photodynamic
treatment on keratoconus patients may start with short-time injury and unchanged
corneal homeostasis, as well as unchanged healing potential, then make benefit on
biomechanical stability after a relative long-term recovery.
Keratoconus keratocytes appear to have reduced proliferation potential and this
finding could be associated with the altered corneal homeostasis in keratoconus.
Further studies are required in order to delineate the complex mechanisms of
hormonal influences on corneal cell physiology and homeostasis, especially in
keratoconus.
Our results suggest that hormonal influences may modulate the secretion of
interleukins and growth factors by human corneal keratocytes in vitro, thereby
affecting the inflammatory response in corneal stroma. The effects are different in
normal and keratoconus keratocytes, which may reflect the alteration of receptors
expression by corneal keratocytes in keratoconus. Further studies are required in order
to delineate the pathophysiological mechanisms underlying the hormonal modulation
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of inflammatory response mediated by human corneal keratocytes.
Crosslinking/riboflavin-UVA-PDT decreases viability, triggers apoptosis and inhibits
proliferation, however it does not have an impact on multipotent haematopoietic stem
cell transformation and myofibroblastic transformation of human KC keratocytes in
vitro. We oppose the idea that crosslinking may induce bacterial or acanthamoeba
keratitis. Alterations of intracellular pathways following crosslinking have to be
further analysed in the future.
Growth factor and interleukin secretion of normal and keratoconus keratocytes differs
after crosslinking, dependent on the response of keratocytes (activation or apoptotis)
to the treatment in both conditions (normal and KC keratocytes). Alterations of the
intracellular pathways after crosslinking have to be further analyzed in the future.
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